Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
11010854 | Pharmacological Reports | 2018 | 25 Pages |
Abstract
This study shows that compound 5 is able to counteract the cannabinoid activation induced by the agonist CP 55.940. Further investigations on its pharmacological profile are mandatory before considering it as a potential candidate for clinical studies and its possible employment as pharmacological agent for the management of different pathological conditions such as motor incoordination, obesity and brain related disorders.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Biochemistry
Authors
Fabiana Plescia, Fulvio Plescia, Demetrio Raffa, Angela Cavallaro, Gianluca Lavanco, Benedetta Maggio, Maria Valeria Raimondi, Giuseppe Daidone, Anna Brancato, Carla Cannizzaro,